To include your compound in the COVID-19 Resource Center, submit it here.

Translarna ataluren: Completed Phase III enrollment

PTC completed enrollment of about 220 patients ages 7-16 years with nonsense mutation DMD in the double-blind, placebo-controlled, international Phase III ACT DMD trial evaluating oral Translarna

Read the full 276 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE